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In case of primary hypothyroidism, reactive pituitary hyperplasia can manifest as pituitary (pseudo) macroadenoma. We report
the case of a 12-year-old boy who was evaluated for impaired growth velocity and increased body weight. Because of low insulin-
like growth factor 1 levels and poor response to the growth hormone stimulation test, brain magnetic resonance imaging was
performed and a pituitary macroadenoma was found. Treatment with levothyroxine was started, and thyroid function was
evaluated approximately every 40 days to titrate the dosage. After few months of therapy, the size of the macroadenoma decreased
and growth hormone secretion normalized.*e pituitary returned to normal size in approximately 5 years.*e boy went through
puberty spontaneously and reached a normal adult height. In a patient affected by primary hypothyroidism, reactive pituitary
hyperplasia can cause growth hormone deficiency; however, growth hormone secretion usually normalizes after starting lev-
othyroxine treatment. Pituitarymacroadenoma can be difficult to distinguish from severe pituitary hyperplasia; however, pituitary
macroadenomas are rare in childhood, and our clinical case underlines how the hormonal evaluation is essential to achieve a
correct diagnosis and prevent unnecessary surgery in a context of pituitary mass.
1. Introduction
Pituitary hyperplasia (PH) can be secondary to hypothy-
roidism (HT) as a consequence of high thyrotropin-re-
leasing hormone (TRH) levels that stimulate both pituitary
thyrotroph and lactotroph cells, leading to the enlargement
of the pituitary gland and possibly hyperprolactinemia [1].
PH due to HT needs to be considered, especially in patients
with severe and long-standing HT. In fact, as shown by
Khawaja et al. [2], PH occurs in 70% of children with
primary HT and thyroid-stimulating hormone (TSH)
≥50mIU/L. In some patients, the pituitary gland can be
significantly enlarged and, consequently, a macroadenoma
may be included in the differential diagnosis, in particular
when brainmagnetic resonance imaging (MRI) is performed
before thyroid tests. In childhood, pituitary macroadenomas
are rare, accounting for less than 3% of all brain tumors, and
are often difficult to diagnose. *eir clinical manifestations
include both endocrine and neurological signs and symp-
toms. *e first ones are consequent to pituitary hormone
dysfunction, while the neurological symptoms derive from
the mass effect and can appear later than endocrine alter-
ations and growth impairment [3]. *us, in the suspicion of
a pituitary macroadenoma, a careful endocrine evaluation is
mandatory to avoid unnecessary and dangerous surgical
procedures.
2. Case Description
A 12-year-old boy was evaluated for statural growth de-
celeration and increased weight in a first-level hospital. In
the previous year, the height decreased from the 50th to the
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25th centile and the weight increased from the 50th to the 75th
centile. Personal medical history was silent, and the family
history was positive for autoimmune thyroiditis (his mother
was affected). At the first clinical evaluation, auxological data
were height 145.7 cm (−0.69 SDS), weight 39.05 kg, body
mass index (BMI) 18.4 kg/m2 (0.29 SDS), Tanner’s stages
A1-P3-G3, and testicular volume 8ml on both sides. *e
general physical examination was normal, except for mild
facial swelling. Extremely increased value of TSH associated
to low free thyroxine (FT4) and antithyroid antibodies led to
the diagnosis of Hashimoto’s disease: TSH 1748 µU/ml
(normal value 0.4–4.0), FT4 0.10 ng/dl (normal value
0.6–1.1), thyroid peroxidase antibody (TPOAb)> 1000 IU/
ml (normal value< 6), and thyroglobulin antibody (TgAb)
587 IU/ml (normal value< 4). Ultrasound examination of
the thyroid gland supported the diagnosis of autoimmune
thyroiditis. Because of growth deceleration associated to
insulin-like growth factor 1 (IGF-1) below the normal range
for age, despite that the HT already explained the growth
deceleration, a first stimulation test with arginine was
performed to evaluate growth hormone (GH) secretion and
an insufficient hormone response was demonstrated (GH
peak 3.9 ng/ml). Bone age conformed to chronological age.
*e brain MRI showed an enlarged pituitary gland, with
globular appearance and bulge of the upper profile, causing
the stretching of the pituitary stalk. *e mass measured
19mm× 11mm× 17 , and it reached the suprasellar cistern,
imprinting the anterior portion of the optic chiasm; no
cleavage plans with the cavernous sinus were evident bi-
laterally. After gadolinium administration, homogeneous
enhancement was registered.*e image was compatible with
pituitary macroadenoma. At this time, after about 2.5
months, the patient was referred to our center for a second
opinion. In view of high TSH levels associated with low
levels of FT4 and GH, the suspicion of GH deficiency (GHD)
secondary to pituitary hyperplasia associated to primary HT
was raised. In the meanwhile, we started treatment with
levothyroxine at 12.5 µg/kg/day and thyroid function was
evaluated approximately every 40 days to titrate the dosage
(Figure 1(a)). After 3 months, when fT4 reached stable
normal values, a second GH stimulation test demonstrated a
normal GH peak (14 ng/ml). At this time, a first reduction of
the pituitary enlargement was registered at MRI follow-up
(Figure 1(b)). *e boy was evaluated for the last time when
he was 17 years and 7 months old: his final height was
normal (−0.09 SDS), both weight and BMI were appropriate,
and complete pubertal development was achieved. *e last
MRI showed a normal pituitary gland, with uniform signal,
centered pituitary stalk, and normal optic chiasm.
3. Discussion
Primary hypothyroidism in childhood often occurs with
unspecific symptoms and signs: among these, deceleration of
height growth and gain of body weight can be the pre-
dominant clinical manifestations [4]. Due to the increased
availability of MRI, brain imaging is more and more often
performed at an early stage of the diagnostic workup for
impaired growth. In case of severe primary hypothyroidism,
reactive pituitary hyperplasia is not unusual, but because of
the similarity between the imaging of pituitary macro-
adenoma and severe pituitary hyperplasia, the differential
diagnosis can be challenging. In particular, if MRI is in-
correctly performed before thyroid function tests, PH sec-
ondary to HT can be misdiagnosed with a macroadenoma.
In fact, when the size of the pituitary gland is highly in-
creased, growth deceleration can develop and might be
incorrectly attributed to the compression of a pituitary
adenoma on the pituitary stalk, resulting in decreased GH
secretion.
Traditional diagnostic criteria for pituitary macro-
adenoma include homogeneous enlargement of the gland
greater than 10mm, with or without erosion of the sellar
floor, and deviation of the stalk [5]. According to the more
recent literature, macroadenomas are frequently asymmet-
ric, the pituitary stalk can be deviated but only rarely
thickened, the posterior pituitary bright spot is preserved,
and the sellar floor can be eroded [6]. After gadolinium
administration, pituitary hyperplasia reveals typically ho-
mogeneous enhancement on TI-W images while a macro-
adenoma may show either homogeneous or heterogeneous
enhancement [7].
To discuss deeper the risk of misdiagnosis between pi-
tuitary macroadenoma and PH secondary to HT, we per-
formed a literature research on the PubMed database using
the combination of (primary hypothyroidism) AND (pi-
tuitary macroadenoma) AND (pediatric OR children). A
total of 32 articles were provided, dated up to December
2020. Of these, three were excluded because the text was
available only in Chinese, seventeen were excluded on the
basis of the title and/or the abstract, and three were not
included because the authors described a pituitary hyper-
plasia and not a pituitary adenoma (moreover, one of these
case reports referred to a lady 29 years old, therefore outside
the pediatric age). Of the nine case reports left, one was a
letter to the editor written in response to one of the eight
papers left that represent the final result of our selection
(Table 1) [8–15].
Among the cases described, three patients underwent brain
MRI as first exam because of neurological symptoms: one
patient referred nausea and vomiting since ten months [8], the
second patient presented with frontal headache, lethargy, and
dizziness since two months [10], and the third patient com-
plained of persistent occipital headache and growth arrest since
three months [14]. In one of the two cases described by Young
et al. [9], the MRI was performed before thyroid tests because
the girl presented with galactorrhea and prolactin was in-
creased [9]. In other patients, MRI was performed precociously
for diminished growth velocity and excessive weight gain
[9, 11] or for aspecific symptoms including headaches [12]. In
all patients, a pituitary mass suggestive of macroadenoma was
found. During the assessment of pituitary function, high levels
of TSH associated with low levels of FT4 were detected and
allowed the diagnosis of primary hypothyroidism.*e pituitary
mass was reinterpreted as pituitary hyperplasia, and the right
treatment was started. On the other hand, brain MRI was also
performed in some patients after hormonal workup for re-
duced GH levels [13, 15], as in the case we reported.
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Figure 1: Biochemical and radiological follow-up. (a) TSH and FT4 values during levothyroxine treatment titration. (b) Reduction of the
pituitary mass size during levothyroxine treatment, in a follow-up of around 5 years.
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All cases we discussed show that, in the presence of a
pituitary mass, it is essential to correlate imaging findings
with hormonal evaluation, above all when brain MRI is
performed for nonspecific neurological symptoms (such as
headache) and, thus, before endocrine laboratory workup. In
the presence of extremely high levels of TSH, a diagnosis of
TSH-secreting adenoma should be excluded, but in this case,
FT4 levels would be increased [12]. When high levels of TSH
are associated with low levels of FT4, the finding of an
increased pituitary gland on MRI imaging should be at-
tributed firstly to PH secondary to HT. In this condition, the
size of the pituitary will decrease after treatment with lev-
othyroxine and unnecessary (and even dangerous) surgery is
spared.
Moreover, it is conceivable that the extreme hypertrophy
of thyrotroph cells leads to compression of the surrounding
cells, causing mainly GHD and, as a consequence, growth
deceleration. Usually, GH replacement therapy is not needed
because impaired GH secretion often resolves after thyroid
hormone replacement therapy [16, 17]. In any case, close
monitoring is strongly recommended and persistence of








MRI: Magnetic resonance imaging
IGF-1: Insulin-like growth factor 1
GH: Growth hormone
GHD: Growth hormone deficiency.
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